IOVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IOVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Iovance Biotherapeutics's ROE % for the quarter that ended in Sep. 2024 was -43.34%. Iovance Biotherapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 3.70. Iovance Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -11.71%.
The historical data trend for Iovance Biotherapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
ROE % Adjusted to Book Value | Get a 7-Day Free Trial | -4.41 | -5.24 | -11.11 | -29.42 | -23.01 |
Iovance Biotherapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
ROE % Adjusted to Book Value | Get a 7-Day Free Trial | -42.00 | -20.78 | -11.72 | -17.30 | -11.71 |
For the Biotechnology subindustry, Iovance Biotherapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's ROE % Adjusted to Book Value falls into.
Iovance Biotherapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as
Iovance Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Iovance Biotherapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Ryan D Maynard | director | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Wayne P. Rothbaum | director | C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019 |
Merrill A Mcpeak | director | PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001 |
Wendy L Yarno | director | |
Frederick G Vogt | officer: General Counsel | 2120 HEMLOCK RD., WEST NORRITON PA 19403 |
Iain D. Dukes | director | 112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120 |
Wendy L Dixon | director | |
Michael Weiser | director | C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133 |
Igor Bilinsky | officer: Chief Operating Officer | C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Jean-marc Bellemin | officer: Chief Financial Officer | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Michael Swartzburg | officer: VP, Finance | C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
Athena Countouriotis | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Finckenstein Friedrich Graf | officer: Chief Medical Officer | 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070 |
Timothy E Morris | officer: Chief Financial Officer | ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Maria Fardis | director, officer: President and CEO | C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
From GuruFocus
By GuruFocus News • 10-09-2024
By GuruFocus News • 11-08-2024
By Marketwired • 08-08-2024
By Marketwired • 09-03-2024
By GuruFocus News • 10-24-2024
By Marketwired • 05-17-2024
By Marketwired • 05-09-2024
By Marketwired • 06-28-2024
By GlobeNewswire • 07-19-2024
By GlobeNewswire • 05-17-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.